

Form PTO-1449 (modified)	Atty. Docket No. <b>BURG047--1/KAM</b>	Serial No. <b>Unknown</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant <b>STANISLAW R. BURZYNSKI</b>	
	Filing Date:	Group: <b>Unknown</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1-2</i>

11046 U.S. PTO  
09/863035  
05/22/01

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
Q	A1	4,470,970	9/11/84	Burzynski	424	177	
Q	A2	5,605,930	2/25/97	Samid	514	510	
Q	A3	5,254,587	10/19/93	Burzynski	514	563	
Q	A4	4,284,647	08/18/81	Brusilow	424	317	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
Q	B1	WO 93 24123	12/9/93	WIPO			
Q	B2	WO 97 42939	11/20/97	WIPO			

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
Q	C1	Burzynski et al., "Toxicology Studies on Antineoplaston AS2-1 Injections in Cancer Patients," <i>Drugs. Exptl. Clin. Res.</i> , Suppl. 1, XII:25-35 (1986)
Q	C2	Burzynski et al., "Preclinical Studies on Antineoplaston AS2-1 and Antineoplaston AS2-5," <i>Drugs. Exptl. Clin. Res.</i> , Suppl. 1, XII:11-16 (1986)
Q	C3	Prados et al., "Protocol NABTC 9402: Phase II Trial of Phenylacetic Acid for Recurrent Malignant Glioma," <a href="http://cc.ucsf.edu/Pr/NATBTC_9402.pr.html">http://cc.ucsf.edu/Pr/NATBTC_9402.pr.html</a> , pp. 1-13 (8/29/96)
9	C4	Buckner et al., "Phase II Study of Antineoplastons A10 (NSC 648539) and AS2-1 (NSC620261) in Patients with Recurrent Glioma," <i>MAYO CLINIC PROCEEDINGS</i> , vol. 74, no. 2, 1 February 1999, pages 137-145
Q	C5	Chang et al, "Phase II Study of Pheylacetate in Patients with Recurrent Malignant Glioma: A North American Brain Tumor consortium Report", <i>JOURNAL OF CLINICAL ONCOLOGY</i> , vol. 17, no. 3, March 1999, pages 984-990

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. BURG047--1/KAM	Serial No. Unknown
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant STANISLAW R. BURZYNSKI	
		Filing Date:	Group: Unknown
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1-2	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
2	C6	Thibault et al, "Phase I Study of Pheylacetate Administered Twice Daily to Patients with Cancer", CANCER, vol. 75, 1995, pages 2932-2938
2	C7	Thibault et al, "A Phase I Study of the Differentiating Agent Phenyl Utyrate in Patients with Cancer", ANNALS OF ONCOLOGY, VOL. 7, No. s1, 1996, page 63
9	C8	Piscitelli, Stephen C. et al, "Disposition of Phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine", J. CLIN. PHARMACOL. (1995), 35(4), 368-73
9	C9	Burzynski and Kubove, "Toxicology Studies on Antineoplastic A10 Injections in Cancer Patients", DRUGS EXPTL. CLIN. RES., vol. 12 no. s1, 1986, pages 47-55
9	C10	Burzynski, "Toxicology Studies on Antineoplaston AS2-5 Injections in Cancer Patients:", DRUGS EPTL. CLIN. RES., vol. 12, no. s1, 1986, pages 17-24
9	C11	Ashraf et al. "Preclinical Studies on Antineoplaston A10 Injections"; <u>Drugs. Exptl. Clin. Res.</u> ; Suppl. 1, XII, 37-45 (1986)
2	C12	Tsuda et al., "Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma"; <u>The Kurume Medical Journal</u> ; (1996) Vol. 43:137-147

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)